title: What is the appropriate MHRA regulatory response to calcium's increased cardiovascular risk?
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Bolland
authors.forename: Alison
authors.initials: A
authors.lastname: Avenell
authors.forename: Andrew
authors.initials: A
authors.lastname: Grey
authors.forename: Ian R
authors.initials: IR
authors.lastname: Reid
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects; D002118:Calcium / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D017277:Drug Approval; D006077:Government Agencies; D006801:Humans; D009942:Organometallic Compounds / Q000009:adverse effects; D012307:Risk Factors; D013876:Thiophenes / Q000009:adverse effects; D006113:United Kingdom
chemical_list: D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate; D002118:Calcium